▲[A panoramic view of the breast milk oligodang plant completed in Hwaseong, Gyeonggi Province in 2018 with the first investment from domestic venture capital.]

HMOs stands for Human Milk Oligosaccharides, a bio-venture company established in 2001 mainly in research and development of recombinant protein manufacturing processes for human breast milk.

2'-FL is a rare sugar that exists only in human breast milk, which specifically grows four to five useful microorganisms, including bifidobacterium, in the human body.
It is a key ingredient in breast milk that inhibits the penetration of harmful bacteria or viruses into the body and inhibits inflammatory-related reactions or contributes to the development of nerve cells in the brain to grow healthy.
As of 2019, four companies in Europe and the U.S. have obtained permission to manufacture and sell 2'-FL, and large companies such as BASF and Dupont have declared their participation, drawing keen attention from the global food industry.

It is also establishing a production plant on HMOs campus in time for the completion of the permit, which is expected from late 2019 to early 2020.

This product is expected to be a new area of health food that supports lactobacillus' intestinal health improvement function more strongly, mitigates inflammation through breast milk and sugar-specific immune activation, and combines brain health improvement functions.

Related Article Shortcut: Gyeonggi-do Min Ilbo (http://www.kgdm.co.kr)